XML 24 R13.htm IDEA: XBRL DOCUMENT
v3.22.2

Accrued Liabilities | 6 Months Ended
--- | ---
Jun. 30, 2022
Payables and Accruals [Abstract] |
Accrued Liabilities | Accrued Liabilities As of June 30, 2022 and December 31, 2021, the Company's accrued liabilities balance consists of the following (in thousands):
| June 30, 2022 |  | December 31, 2021
Accrued clinical trial expenses | $ | 17,019 |  |  | $ | 19,410 |
Accrued professional fees | 11,336 |  |  | 10,678 |
Accrued technical operation expenses | 4,816 |  |  | 6,187 |
Accrued royalty payable | 7,182 |  |  | 6,655 |
Accrued interest payable | 2,175 |  |  | 2,175 |
Accrued sales allowances and related costs | 11,470 |  |  | 8,275 |
Deferred consideration | 3,459 |  |  | 4,883 |
Accrued construction costs | 105 |  |  | 551 |
Other accrued liabilities | 1,208 |  |  | 1,851 |
| $ | 58,770 |  |  | $ | 60,665 |

X
- Definition The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19(a),20,24) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_PayablesAndAccrualsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration